493 related articles for article (PubMed ID: 17249907)
1. Results of retrospective chart review to determine improvement in lipid goal attainment in patients treated by high-volume prescribers of lipid-modifying drugs.
Stacy TA; Egger A
J Manag Care Pharm; 2006; 12(9):745-51. PubMed ID: 17249907
[TBL] [Abstract][Full Text] [Related]
2. LDL-C goal attainment among patients newly diagnosed with coronary heart disease or diabetes in a commercial HMO.
Nag SS; Daniel GW; Bullano MF; Kamal-Bahl S; Sajjan SG; Hu H; Alexander C
J Manag Care Pharm; 2007 Oct; 13(8):652-63. PubMed ID: 17970603
[TBL] [Abstract][Full Text] [Related]
3. Lipid levels and use of lipid-lowering drugs for patients in pharmacist-managed lipid clinics versus usual care in 2 VA Medical Centers.
Mazzolini TA; Irons BK; Schell EC; Seifert CF
J Manag Care Pharm; 2005; 11(9):763-71. PubMed ID: 16300420
[TBL] [Abstract][Full Text] [Related]
4. Current lipid management and low cholesterol goal attainment in common daily practice in Spain. The REALITY Study.
García Ruiz FJ; Marín Ibáñez A; Pérez-Jiménez F; Pintó X; Nocea G; Ahumada C; Alemao E; Yin D;
Pharmacoeconomics; 2004; 22 Suppl 3():1-12. PubMed ID: 15669149
[TBL] [Abstract][Full Text] [Related]
5. Effectiveness of a pharmacy care management program for veterans with dyslipidemia.
Smith MC; Boldt AS; Walston CM; Zillich AJ
Pharmacotherapy; 2013 Jul; 33(7):736-43. PubMed ID: 23625745
[TBL] [Abstract][Full Text] [Related]
6. Low-density lipoprotein cholesterol (LDL-C) levels and LDL-C goal attainment among elderly patients treated with rosuvastatin compared with other statins in routine clinical practice.
Harley CR; Gandhi S; Blasetto J; Heien H; Sasane R; Nelson SP
Am J Geriatr Pharmacother; 2007 Sep; 5(3):185-94. PubMed ID: 17996658
[TBL] [Abstract][Full Text] [Related]
7. Prevalence of dyslipidemia and lipid goal attainment in statin-treated subjects from 3 data sources: a retrospective analysis.
Jones PH; Nair R; Thakker KM
J Am Heart Assoc; 2012 Dec; 1(6):e001800. PubMed ID: 23316314
[TBL] [Abstract][Full Text] [Related]
8. Residual dyslipidemia among United States adults treated with lipid modifying therapy (data from National Health and Nutrition Examination Survey 2009-2010).
Wong ND; Chuang J; Wong K; Pham A; Neff D; Marrett E
Am J Cardiol; 2013 Aug; 112(3):373-9. PubMed ID: 23642513
[TBL] [Abstract][Full Text] [Related]
9. Pitavastatin: novel effects on lipid parameters.
Chapman MJ
Atheroscler Suppl; 2011 Nov; 12(3):277-84. PubMed ID: 22152282
[TBL] [Abstract][Full Text] [Related]
10. One-year efficacy and safety of rosuvastatin + fenofibric acid combination therapy in patients with mixed dyslipidemia: evaluation of dose response.
Ferdinand KC; Davidson MH; Kelly MT; Setze CM
Am J Cardiovasc Drugs; 2012 Apr; 12(2):117-25. PubMed ID: 22263674
[TBL] [Abstract][Full Text] [Related]
11. Risk of cardiovascular events in patients at optimal values for combined lipid parameters.
Stanek EJ; Sarawate C; Willey VJ; Charland SL; Cziraky MJ
Curr Med Res Opin; 2007 Mar; 23(3):553-63. PubMed ID: 17357251
[TBL] [Abstract][Full Text] [Related]
12. Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting.
Cziraky MJ; Watson KE; Talbert RL
J Manag Care Pharm; 2008 Oct; 14(8 Suppl):S3-28; quiz S30-1. PubMed ID: 19891279
[TBL] [Abstract][Full Text] [Related]
13. Lipid-lowering therapy and lipid goal attainment in patients with metabolic syndrome in China: subgroup analysis of the Dyslipidemia International Study-China (DYSIS-China).
Wang F; Ye P; Hu D; Min Y; Zhao S; Wang Y; Mu Y; Yan X; Li Z; Wei Y; Li J;
Atherosclerosis; 2014 Nov; 237(1):99-105. PubMed ID: 25238215
[TBL] [Abstract][Full Text] [Related]
14. Attainment of goal/desirable lipid levels in patients with mixed dyslipidemia after 12 weeks of treatment with fenofibric acid and rosuvastatin combination therapy: a pooled analysis of controlled studies.
Roth EM; Rosenson RS; Jones PH; Davidson MH; Kelly MT; Setze CM; Lele A; Thakker K
J Clin Lipidol; 2012; 6(6):534-44. PubMed ID: 23312049
[TBL] [Abstract][Full Text] [Related]
15. The relationship between nonfasting and fasting lipid measurements in patients with or without type 2 diabetes mellitus receiving treatment with 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors.
Weiss R; Harder M; Rowe J
Clin Ther; 2003 May; 25(5):1490-7. PubMed ID: 12867223
[TBL] [Abstract][Full Text] [Related]
16. Secondary prevention in a cardiology group practice and hospital setting after a heart-care initiative.
LaBresh KA; Owen P; Alteri C; Reilly S; Albright PS; Hordes AR; Shaftel PA; Noonan TE; Stoukides CA; Kaul AF
Am J Cardiol; 2000 Feb; 85(3A):23A-29A. PubMed ID: 10695704
[TBL] [Abstract][Full Text] [Related]
17. Prevalence and overlap of different lipid abnormalities in statin-treated patients at high cardiovascular risk in clinical practice in Germany.
Gitt AK; Jünger C; Smolka W; Bestehorn K
Clin Res Cardiol; 2010 Nov; 99(11):723-33. PubMed ID: 20521058
[TBL] [Abstract][Full Text] [Related]
18. Residual dyslipidemia according to low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B among statin-treated US adults: National Health and Nutrition Examination Survey 2009-2010.
Wong ND; Chuang J; Zhao Y; Rosenblit PD
J Clin Lipidol; 2015; 9(4):525-32. PubMed ID: 26228670
[TBL] [Abstract][Full Text] [Related]
19. Low-density lipoprotein apheresis: an evidence-based analysis.
Medical Advisory Secretariat
Ont Health Technol Assess Ser; 2007; 7(5):1-101. PubMed ID: 23074505
[TBL] [Abstract][Full Text] [Related]
20. Lipid attainment among patients newly treated with lipid-altering drugs.
Hess G; Chang CL; Chung K
Curr Med Res Opin; 2014 Sep; 30(9):1743-56. PubMed ID: 24889282
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
